Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Total Liabilities
Everything the company owes to creditors and other parties.
Beta Bionics, Inc.NASDAQ: BBNX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 36.7% from a year ago
Total liabilities stood at $33.17M at the end of Q1 FY2026, up 36.7% from a year earlier and down 19.4% from the prior quarter. Over 3 fiscal years it compounded at +22.2% a year.
Context
- Total liabilities amounted to 10.9% of total assets at the end of Q1 FY2026, up 3.7 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +36.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 41.13M USD
- Year-over-year change
- -44.1%
- 3-year CAGR
- +22.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.13M | -44.1% |
| FY2024 | 2024-12-31 | 73.63M | +43.2% |
| FY2023 | 2023-12-31 | 51.43M | +128.3% |
| FY2022 | 2022-12-31 | 22.53M | — |
Total Liabilities vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +36.7% is the 3rd highest of 7, against a peer median of +26.1%.
- Total liabilities amounts to 10.9% of total assets for BBNX, versus a peer median of 59.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 373.66B DKK | +19.0% | +30.3% | 62.8% | |
| Jun 2026 | $3.83B USD | -19.4% | +3.3% | 59.4% | |
| Jun 2026 | $1.74B USD | -13.1% | -1.9% | 55.1% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $1.1B USD | — | — | 23.3% |
| Mar 2026 | $1.02B USD | +33.1% | +5.8% | 88.5% | |
| Mar 2026 | $803.6M USD | +71.4% | +15.6% | 108.0% | |
| Mar 2026 | $33.17M USD | +36.7% | +22.2% | 10.9% | |
| Mar 2026 | $30.57M USD | +299.9% | +43.7% | 11.4% | |
| Peer median (excluding BBNX) | — | +26.1% | +10.7% | 59.4% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.